AOD 9604 had six human trials and 900 participants. Phase IIa showed positive results. Then the pivotal Phase IIb failed at every dose tested. Development was terminated in 2007. The trial history is AOD 9604: Peptide Claims vs Clinical Reality, AOD 9604 is marketed as a fat metabolism peptide derived from a growth hormone fragment, often positioned as HGH like without HGHs side effects. The AOD9604 Peptide for Fat Loss in 2025: LateNight Hype, Quiet Results, and What Nobody Tells You AOD 9604 Peptide: Fat Loss, Before and After Results, and How It Works AOD 9604 Peptide: The Complete Guide to Targeted Fat Loss, Dosage Protocols, and the Clinical Science Behind the Most Specific Lipolytic Peptide: Endura Science Books: 9798255237043: Amazon.com: Books Peptide Dosage Cheat Sheet PDF Medicinal Chemistry Medical Treatments